Quality of life in osteoporotic women with inadequate clinical response to antiresorptive drugs: results from the ICARO study.

Treatment adherence and QoL with intermittent PTH therapy: Results from a multicentre Italian study after 6 months

Improvement of quality of life during treatment with anabolic therapy: Results of a multicenter study

Efficacy and safety of daily treatment with parathyroid hormone were evaluated in a typical Italian population with severe post-menopausal osteoporosis eligible to anabolic treatment (Nota 79 AIFA). Materials and methods: 204 ambulatory female patients (median age: 72.6±8.3 years; height: 155.3±6.5 cm; weight: 61.1±11.9 Kg) with severe post-menopausal osteoporosis have been enrolled in this study accordingly to summary of product characteristics and Italian reimbursement criteria for osteoporosis drugs (Nota 79 AIFA), between January 2008 and April 2009 (Last Patient Out: October 2010). 146 (71.57%) out of these patients completed the study.6 visits were planned in the study protocol: basel…

Treatment adherence and QoL with intermittent PTH therapy: Results from a multicentre Italian study after 6 months

This ongoing multicentre study was carried out to investigate the adherence to intermittent parathyroid hormone treatment and the effect on QoL in a typical Italian population eligible for drug reimbursement (i.e. a new vertebral or hip fracture following at least one year of anti-resorptive therapy or three severe vertebral fractures or two severe and one femur fracture). 204 female patients (mean age: 72.6±8.3) were enrolled between March 2008 and April 2009. These patients were treated with PTH (PTH 1–34 or PTH 1–84) according to Italian legislation. Here, we report the results obtained at month 6.

IL SILENZIO VERDE. CONTRIBUTO AI PIANI PAESISTICI NELL'AREA DA SELINUNTE A ERACLEA MINOA

PARATHYROID HORMONE INCREASES AFTER ORAL PEPTONES ADMINISTRATION IN OBESE SUBJECTS TREATED WITH ROUX-EN-Y GASTRIC BYPASS SURGERY: ROLE OF PHOSPHATE ON THE RAPID CONTROL OF PARATHYROID HORMONE RELEASE

The Italian observational study on severe osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe ver…